Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

European Research Council grant · Running

MEGI CD Metabolic Gut Inflammation in Crohn's disease

Coordinator
Medizinische Universitat Innsbruck, Austria
Runs
1 April 2022 to 31 March 2027
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101039320

What the project is doing

In the project's own words, from its summary on CORDIS.

The rising incidence of inflammatory bowel diseases such as Crohn?s disease (CD) has become a global health care issue in the 21st century. The complex genetic underpinning is increasingly appreciated, while environmental cues and specifically a Western diet are suspected to impact development and course of disease. Mechanistic insights that would support this assumption remain scarce and specific nutrients that trigger a flare are unknown.

Westernisation of dietary habits is partly characterised by enrichment of long-chain fatty acids, which fuel metabolic inflammation of tissues beyond the gut. Here, we propose to establish the concept of metabolic gut inflammation as a fuel for CD. By analysing transgenic mice, human CD organoids and two independent CD patient cohorts, we seek to establish how dietary polyunsaturated fatty acids (PUFAs) affect gut inflammation and disease course.

The proposed work is based on our previous observations that dietary PUFAs trigger a chemokine response and Crohn?s-like enteritis in mice, which is restricted by intestinal epithelial Glutathione peroxidase 4 (GPX4). GPX4 is an evolutionary conserved anti-oxidative enzyme which shows impaired activity in CD epithelium. The proposed work will identify how dietary PUFAs elicit gut inflammation in mice and which epithelial lineage executes the inflammatory response.

In a next step, I propose to establish a critical crosstalk between GPX4 and metabolic hubs in gut epithelium to provide a basis for the concept of metabolic gut inflammation. Finally, we seek to translate findings by establishing that PUFAs evoke an inflammatory response from CD epithelium, and that PUFA intake impacts disease course. MEGI CD comprehends basic and translational science to set the basis for novel therapeutic strategies in a complex illness that requires better treatment modalities.

The study will prove the concept of metabolic gut inflammation as a major driver of human CD, a basis for nutritional therapy.

Topics

Who is involved

OrganisationCityCountryRole
Medizinische Universitat InnsbruckInnsbruckAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI